- Research Tracker
- Supplement safety
- Vitamin B12
What public sources say about the safety of vitamin B12: FDA adverse-event reports, NIH guidance on interactions with medicines, and the registered trials that test it.
Interactions and safety, in NIH's words
Vitamin B12 supplements may interact with medications, and some medications, including gastric acid inhibitors and metformin, may affect vitamin B12 levels.
Vitamin B12 supplements have the potential to interact with certain medications. In addition, several types of medications might adversely affect vitamin B12 levels. A few examples are provided below. Individuals taking these and other medications on a regular basis should discuss their vitamin B12 status with their health care providers.
Gastric acid inhibitors include proton pump inhibitors, such as omeprazole (Prilosec) and lansoprazole (Prevacid), and histamine 2-receptor antagonists, such as cimetidine (Tagamet) and ranitidine (Zantac). These drugs are used to treat gastroesophageal reflux disease and peptic ulcer disease. They can interfere with vitamin B12 absorption from food by slowing the release of gastric acid into the stomach and thereby lead to vitamin B12 deficiency [101-103].
Medicines covered in that section: Gastric acid inhibitors, Metformin.
Quoted from the “Interactions with Medications” section: NIH Office of Dietary Supplements, health-professional fact sheet, retrieved 2026-11-16. Read the full page for the complete list and references.
FDA adverse-event reports (CAERS)
Matching rule: reports in the dietary-supplement category where a product marked "suspect" has a brand name containing “VITAMIN B12”, “VITAMIN B-12”, “B12”. Products that contain it without naming it are missed. Reports where it was only taken alongside the suspect product are not counted.
Combination products: 32 of the reports involve only products whose name lists another ingredient, such as calcium or a multivitamin. Their reactions may come from that other ingredient or from the tablet itself, so the reactions below count only the 159 reports where a product is named for vitamin B12 alone. This split is made from product names and can misfile some products. Most-reported products: Vitamin B12 (12); B12 Energy Berry Melts (10); Emergen-C Lite With Msm (5); Puritan'S Pride Vitamin B-12 (4); Naturemade Vitamin B12 (3); Vitamin B-12 (3).
| Most reported reactions (single-ingredient products) | Reports |
|---|---|
| Dyspnoea | 20 |
| Nausea | 17 |
| Diarrhoea | 16 |
| Malaise | 16 |
| Urticaria | 13 |
| Headache | 12 |
| Pruritus | 11 |
| Dizziness | 11 |
| Fatigue | 10 |
| Vomiting | 10 |
| Hypersensitivity | 10 |
| Throat tightness | 9 |
Outcomes recorded in these reports (a report can have several): Other Serious or Important Medical Event (110), Hospitalization (38), Visited a Health Care Provider (36), Visited Emergency Room (35), Other Serious Outcome (14), Life Threatening (11), Other Outcome (9), Disability (8).
Source: openFDA food and supplement adverse events (CAERS), retrieved 2026-11-16.
Registered trials
154 trials in the non-drug evidence map test this class of supplement. Trials with posted results are listed first; each shows the condition it was registered for. A trial testing it in one condition says nothing about another.
- Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder Completed Results posted
- Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer Completed Results posted
- Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEY Completed Results posted
- Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEY Completed Results posted
- A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer Completed Results posted
- Exercise Intolerance in Renal Failure Completed Results posted
- Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout Completed Results posted
- Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout Completed Results posted
- Telehealth Delivery (Tele-B6) Completed Results posted
- Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications Completed Results posted
- Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment Completed Results posted
- A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer Completed Results posted
- Phase 2 Trial of Bevacizumab in Combination With Pemetrexed Completed Results posted
- Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC Completed Results posted
- A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer Completed Results posted
- Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Completed Results posted
- Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma Completed Results posted
- Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Completed Results posted
- A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL Completed Results posted
- GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response Completed Results posted